Immunology
The Journal of cells, molecules, systems and technologies

British Society for immunology

IMMUNOLOGY CORRIGENDUM

Corrigendum

The article[1] should be read with reference to new data[2] for the correct specificity of the CD6 mAbs, OX124, OX125 and OX126.[3,4] Domain specificity for OX124, OX125 and OX126 should be deleted and the name of the antibody given. As the focus of the article is domain 1 mAbs, the overall conclusions are not altered.

Specific alterations to the text are:

Summary, p273. CD6 domain 1, **OX125 and OX126** mAbs were equally effective in triggering interleukin-2 production. . .. . ..CD6 domain 1 mAbs hindered binding of multivalent immobilised CD166 but were inferior compared with blocking by soluble CD166 or **another CD6 mAb**.

Introduction, p274. Immunisation with soluble recombinant CD6 led to the production of **novel** CD6 mAbs[(6)].

Materials and Methods, Monoclonal antibodies, p274. CD6, **OX124 (mouse IgG1), OX125 (mouse IgG2b) and OX126 (mouse IgG1)**[(6)]

Materials and Methods, Flow cytometry, p275. **CD6 mAb** (OX126)

Results, p277 and Figure 3. CD6 domain 1**, OX125 and OX126** mAbs. . ...

Results, p278. . . .CD6 mAbs, OX124, OX125 and OX126 specific for different epitopes on **CD6** for efficacy . . .a **CD6 mAb**, OX125. . . interfere with **OX126** binding to CD6. We began by asking do CD6 domain 1 mAbs hinder binding of OX126[(6)]. . .. . .interactions of **OX126**.

Results, p279 and Figure 4. **CD6 mAb**, OX126.

Results, p279 and Figure 5. The data (Figure 5) are inconsistent with the specificity of OX126[2] and indicate an antibody labelling error.[3,4] Read: CD6 domain 1 mAbs are less effective compared with **another CD6 mAb**. . ..another CD6 mAb which was superior. . ..**another CD6 mAb** was more effective >UMCD6>itolizumab at

Discussion, p280. binding to **domain 1 and by OX125 or OX126** in the efficacy of triggering..

Discussion, p281. . .competition experiment with a CD6 mAb, OX126..Delete text: "As none . . .soluble CD166[(6)]". UMCD6 is not as efficacious at blocking CD6/CD166 interactions compared with **another CD6** mAb

References

1 Garner LI, Hartland A, Breuning J, Brown MH. CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action. *Immunology* 2018; **155**:273–82.
2 Santos RF, Oliveira L, Brown MH, Carmo AM. Domain-specific CD6 monoclonal antibodies identify CD6 isoforms generated by alternative-splicing. *Immunology* 2019; **155**:273–82.
3 Hassan NJ, Simmonds SJ, Clarkson NG, Hanrahan S, Puklavec MJ, Bomb M *et al*. Second correction for Hassan et al., CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76. *Mol Cell Biol* 2019; **39**:e00054-19.
4 Hassan NJ, Simmonds SJ, Clarkson NG, Hanrahan S, Puklavec MJ, Bomb M *et al*. CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76. *Mol Cell Biol* 2006; **26**:6727–38.

